MedCity Pivot Podcast: Precision Medicine with the CEO of Helix
In this episode of the MedCity Pivot Podcast, editor-in-chief Arundhati Parmar, speaks with Helix CEO James Lu about his company and how far precision medicine has come.
Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study
Alzheon hoped testing its drug in a genetically defined subgroup of Alzheimer’s disease patients would succeed, overcoming earlier clinical trial failures. Instead, preliminary results show the pill failed to outdistance a placebo.
presented by
The 6 Most Affordable Workflow Optimization Tools for Radiology
Radiologists today face a surge in imaging volume and pressure to produce fast, accurate reports. Workflow optimization is about delivering the right results at the right time with less friction.
“Precision Med Has Evolved as Badly As I Expected” And Other Takeaways From Former FDA Commissioner At PMWC
Robert Califf addressed a range of issues, including AI, lack of nutrition resources at the FDA and how he evaluates the progress of precision medicine at the Precision Medicine World Conference in Silicon Valley.
Precision Medicine: Becoming More Real With AI?
With technology advancements specifically in the field of AI, there is a clear line of sight in making it mainstream. Here are some of the ways AI is helping to accelerate the adoption of PM.
From Reactive to Proactive: How Precision Medicine Transforms the Break-and-Fix Healthcare System
Reacting to an adverse medical event after it has progressed to causing the patient to seek medical help is the least opportune time to address the underlying disease.
Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.
presented by
Everything You Need to Know About Who Accredits Health Plans for Mental Health Parity Compliance
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
Personalized Medicine Is Revolutionizing the Role of Pharma Companies in the Healthcare Landscape
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer
Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.
Key Trends from the 2024 J.P. Morgan Healthcare Conference
Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.
Goldman Sachs Closes $650M Fund to Invest in ‘Golden Era’ of Biotech Innovation
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
AI Can Make Precision Medicine More Accessible to Patients Who Might Not Have Been Able to Benefit in the Past
“Precision medicine” is a term we have heard a lot over the last two decades, promising to improve health outcomes by pairing the patient with the right treatment. In cancer, we do this primarily with biomarkers. Our understanding of biomarkers – signatures of key features of a tumor – and their role in disease has […]
Season 2 of MedCity Pivot Podcast Launches with Conversation of Zephyr AI CTO
Season 2 of our MedCity Pivot Podcast launches today with a conversation about how AI can be leveraged to transform precision medicine.
Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform
Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.
Improving Value-based Care with Optimized Drug Therapy
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
Nest Genomics Raises $8.5M to Increase Access to Patients’ Genetic Information
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.